Reirradiation for recurrent high-grade glioma: practical guidance on patient selection and cumulative dose

Expert guidance outlines OAR-driven reirradiation using cumulative EQD2, individualized fractionation, and focused target volumes, without proven overall survival benefit.

KEY POINTS

  • This expert review from Mass General Brigham examines contemporary evidence for reirradiation in recurrent high-grade glioma and glioblastoma, including conventional IMRT/VMAT, hypofractionated stereotactic RT, radiosurgery, proton therapy, and pulsed reduced-dose-rate RT. Patient selection, target volume, interval since previous irradiation, cumulative normal-tissue dose, and goals of care are emphasized as the principal determinants of treatment feasibility.
  • The strongest randomized evidence comes from NRG/RTOG 1205, which compared bevacizumab alone with bevacizumab plus 35 Gy in 10 fractions in 170 patients with recurrent glioblastoma. Median progression-free survival was 7.1 versus 3.8 months, respectively, while median overall survival was 10.1 versus 9.7 months, demonstrating improved disease control without a corresponding overall survival benefit.
  • Proton therapy may reduce additional integral dose to previously irradiated normal brain and critical structures. In a contemporary retrospective series of 89 recurrent glioblastoma patients treated with hypofractionated proton reirradiation, grade 3–4 radiation necrosis occurred in 5 patients (5.6%), with no reported optic neuropathy or brainstem necrosis; however, comparative superiority over photon techniques remains unproven.
  • The review discusses proposed cumulative EQD2 ranges from the ReCog collaborative analysis: approximately 75–80 Gy for the optic apparatus, 85–100 Gy for the brainstem, and 100–110 Gy for uninvolved brain. These are evidence-informed candidate ranges, not universally validated constraints, and published series differ in dose accumulation methods, toxicity definitions, and assumptions about tissue recovery.
  • The authors describe a more conservative institutional approach using cumulative dose objectives of 65–75 Gy EQD2 for the optic apparatus, 75–90 Gy EQD2 for the brainstem, and 100–120 Gy EQD2 for uninvolved brain, calculated using α/β = 2 Gy. Previous OAR Dmax or D0.03cc is extracted and converted into EQD2 to determine the remaining dose available for reirradiation, with clinical flexibility in carefully selected cases.
  • Patient selection is strongly prognosis-dependent. Aggressive salvage is most appropriate for patients with KPS >70, focal recurrence, and an interval of more than 12 months after initial RT, whereas KPS 60–70 or a 6–12-month interval may warrant a more conservative approach. Diffuse disease, extensive high-dose overlap, rapid neurologic deterioration, or recurrence within six months generally reduce the attractiveness of reirradiation.
  • Fractionation is selected according to the most restrictive OAR, target size, and intended treatment intensity. Examples include 35 Gy in 10 fractions for larger recurrences, 25–30 Gy in five fractions for smaller focal targets, and 20–25 Gy in five fractions for selected palliative situations; target delineation generally prioritizes recurrent contrast-enhancing disease, with selective rather than automatic inclusion of surrounding FLAIR abnormalities.

CLINICAL TAKEAWAY

Reirradiation is a reasonable salvage option for selected patients with recurrent high-grade glioma, particularly when disease is focal, functional status is preserved, and cumulative OAR exposure remains acceptable. The proposed EQD2-based framework offers practical planning guidance, but dose limits, tissue-recovery assumptions, and treatment intensity must be individualized because a consistent overall survival benefit and universally validated CNS retreatment constraints remain lacking.

SOURCE

Practical Radiation Oncology

Browse more research Suggest a correction